- Home
- CURI vs VNDA Comparison
CURI vs VNDA Comparison
Compare CURI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- VNDA
- Stock Information
- Founded
- CURI 2008
- VNDA 2002
- Country
- CURI United States
- VNDA United States
- Employees
- CURI N/A
- VNDA N/A
- Industry
- CURI Movies/Entertainment
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- VNDA Health Care
- Exchange
- CURI Nasdaq
- VNDA Nasdaq
- Market Cap
- CURI 264.7M
- VNDA 249.4M
- IPO Year
- CURI N/A
- VNDA 2006
- Fundamental
- Price
- CURI $4.85
- VNDA $4.51
- Analyst Decision
- CURI Strong Buy
- VNDA Strong Buy
- Analyst Count
- CURI 2
- VNDA 2
- Target Price
- CURI $5.75
- VNDA $16.50
- AVG Volume (30 Days)
- CURI 626.3K
- VNDA 422.6K
- Earning Date
- CURI 11-05-2025
- VNDA 11-05-2025
- Dividend Yield
- CURI 6.60%
- VNDA N/A
- EPS Growth
- CURI N/A
- VNDA N/A
- EPS
- CURI N/A
- VNDA N/A
- Revenue
- CURI $60,840,000.00
- VNDA $203,467,000.00
- Revenue This Year
- CURI $34.06
- VNDA $15.45
- Revenue Next Year
- CURI $11.70
- VNDA $37.82
- P/E Ratio
- CURI N/A
- VNDA N/A
- Revenue Growth
- CURI 11.02
- VNDA 11.78
- 52 Week Low
- CURI $1.47
- VNDA $3.81
- 52 Week High
- CURI $7.15
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- CURI 61.55
- VNDA 46.90
- Support Level
- CURI $4.31
- VNDA $4.54
- Resistance Level
- CURI $4.71
- VNDA $4.64
- Average True Range (ATR)
- CURI 0.22
- VNDA 0.15
- MACD
- CURI 0.04
- VNDA -0.01
- Stochastic Oscillator
- CURI 98.41
- VNDA 8.89
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.